<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265706</url>
  </required_header>
  <id_info>
    <org_study_id>PTV_LAMIS II</org_study_id>
    <nct_id>NCT01265706</nct_id>
  </id_info>
  <brief_title>Livalo Acute Myocardial Infarction Study (LAMIS)</brief_title>
  <official_title>1-year, Prospective, Randomized, Open-label, Parallel Group Observational Study to Evaluate the Safety and Efficacy of 4mg/Day of Pitavastatin Versus 2mg/Day of Pitavastatin in Acute Myocardial Infarction(AMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is performed to observe the incidence of major cardiovascular events in Korean
      patients with AMI after giving pitavastatin 2mg and 4mg longer than 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of TLR-MACE for 1 year after enrollment</measure>
    <time_frame>1 year after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of TVR-MACE for 1 year after enrollment</measure>
    <time_frame>1 year after enrollment</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        AMI patients who are in need to be treated by statins
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with STEMI, NSTEMI

          -  Patients satisfying at least one of the followings

               1. Patients with LDL-C ≥ 130 mg/dL

               2. Patients with LDL-C ≥ 100 mg/dL who are regarded as required cholesterol lowering
                  therapy by the investigator

               3. Patients taking statin are required continuous cholesterol lowering therapy

          -  Patients satisfying at least two of the followings

               1. The change of Ischemic ECG

               2. CK, CK-MB, Troponin-I increased more than two times

               3. The symptom of ACS

        Exclusion Criteria:

          1. Patients with in-stent restenosis after PCI or coronary artery bypass

          2. Patients with cardiogenic shock

          3. Patients with severe heart failure (Left ventricular ejection fraction is less than
             30%)

          4. Patients who are taking cyclosporine

          5. Patients who experienced hypersensitivity to pitavastatin

          6. Patients under dialysis treatment

          7. Patients who are participating other clinical trials

          8. Patients who can not stop taking concomitant drugs

          9. Pregnant or lactating women or suspected pregnancy

         10. Patients who are regarded as ineligible for this study by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Jun Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

